About Event

We’re excited to introduce the first in-person event in the CRISPR 2.0 series with the added value this format brings. Roundtables on preparing for clinical development, workshops on non-viral delivery methods, plenaries on navigating regulatory filings: expect a streamlined track, packed with insight into all aspects of the development pathway.

CRISPR 2.0 will offer you the opportunity to:

crispr favicon

Enhance product safety profiles, overcome immunotoxicity concerns and mitigate against off-target impacts with help from AstraZeneca

crispr favicon

Learn how to deliver CRISPR cargo in a safe, efficacious and tissue-targeted manor, with expertise from those developing the latest in vivo non-viral delivery platforms, including GenEdit and Harvard University

crispr favicon

Explore the freshest developments with optimised CRISPR nucleases and how they are being applied for ‘next-gen’ treatments of different diseases with Emendo Biotherapeutics

crispr favicon

Gain pioneering insight into how these emerging fields of gene editing are displaying exciting preclinical data from Prime Medicine and UC Irvine

crispr favicon

Translate basic research into a viable therapeutic product and understand the unique clinical development challenges associated with CRISPR-based therapies, from Beam Therapeutics and Genentech